Alison Schaefer
University of North Carolina at Chapel Hill
25 Papers
18 Citations
Alison Schaefer is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Mucus & Mucin. The author has an hindex of 7, co-authored 16 publications. Previous affiliations of Alison Schaefer include North Carolina State University.
Chat about Author
Papers
Convolutional neural networks automate detection for tracking of submicron-scale particles in 2D and 3D
TL;DR: The neural network tracker provides unprecedented automation and accuracy, with exceptionally low false positive and false negative rates on both 2D and 3D simulated videos and 2D experimental videos of difficult-to-track species.
191
The Cervicovaginal Microbiota-Host Interaction Modulates Chlamydia trachomatis Infection
Vonetta L. Edwards,S. Smith,Elias McComb,Jeanne Tamarelle,Bing Ma,Michael S. Humphrys,Pawel Gajer,Kathleen Gwilliam,Alison Schaefer,Samuel K. Lai,Mishka Terplan,Katrina Mark,Rebecca M. Brotman,Larry J. Forney,Patrik M. Bavoil,Jacques Ravel +15 more
TL;DR: The vaginal microbiota is believed to protect women against Chlamydia trachomatis, the etiologic agent of the most prevalent sexually transmitted infection (STI) in developed countries, but the mechanism underlying this protection has remained elusive.
138
ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.
Bing Yang,Alison Schaefer,Ying Ying Wang,Justin D. McCallen,Phoebe T. Lee,Jay M. Newby,Harendra Arora,Priya A. Kumar,Larry Zeitlin,Kevin J. Whaley,Scott A. McKinley,William A. Fischer,Dimple Harit,Samuel K. Lai,Samuel K. Lai +14 more
TL;DR: This work demonstrates that antibodies can immobilize virions in airway mucus and reduce access to the airway epithelium, highlighting topical delivery of pathogen-specific antibodies to the lungs as a potential prophylactic or therapeutic approach against emerging viruses or biowarfare agents.
30
Engineering Polymer-Binding Bispecific Antibodies for Enhanced Pretargeted Delivery of Nanoparticles to Mucus-Covered Epithelium.
Justin T. Huckaby,Christina L. Parker,Timothy M. Jacobs,Alison Schaefer,Daniel Wadsworth,Alexander K. Nguyen,Anting Wang,Jay M. Newby,Samuel K. Lai +8 more
TL;DR: This work explored a two-step "pretargeting" approach through engineering a bispecific antibody that binds both cell-surface ICAM-1 and polyethylene glycol (PEG) on the surface of nanoparticles, thereby effectively decoupling cell targeting from particle design and formulation.
18
Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
Morgan D. McSweeney,Ian Stewart,Z. Richardson,Hyun Ah Kang,Yoon A Park,Cheolmin Kim,Karthik Tiruthani,Whitney E. Wolf,Alison Schaefer,Priya A. Kumar,Harendra Aurora,Jeff T. Hutchins,Jong-Moon Cho,Anthony J. Hickey,Soo Young Lee,Samuel Lai +15 more
TL;DR: It is shown that regdanvimab, a potent neutralizing mAb already approved for COVID-19 in several countries around the world, can effectively trap Sars-CoV-2 virus-like-particles in fresh human airway mucus and substantiate nebulized delivery of human antiviral mAbs as a new paradigm in treating SARS-Cov-2 and other respiratory pathologies.
15